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There is a consensus that mass vaccination against SARS-CoV-2 will ultimately end the
COVID-19 pandemic. However, it is not clear when and which control measures can be
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using an age-structured transmission model that has been fitted to age-specific ser-
oprevalence data, hospital admissions, and projected vaccination coverage for Portugal. Our
analyses suggest that the pressing need to restart socioeconomic activities could lead to new
pandemic waves, and that substantial control efforts prove necessary throughout 2021. Using
knowledge on control measures introduced in 2020, we anticipate that relaxing measures
completely or to the extent as in autumn 2020 could launch a wave starting in April 2021.
Additional waves could be prevented altogether if measures are relaxed as in summer 2020
or in a step-wise manner throughout 2021. We discuss at which point the control of
COVID-19 would be achieved for each scenario.
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Mass vaccination against SARS-CoV-2 started in Europein late 2020 and early 20211, and brings hope that theCOVID-19 pandemic can be brought to an end in 2021.
Even though progress towards this goal seems to be on the right
track2, many governments in Europe continue to limit socio-
economic activities to control the pandemic. Despite elaborate
national vaccination schedules, it is unclear when and which
control measures can be relaxed and at which point the control of
the pandemic will be achieved during the vaccination pro-
gramme. Understanding of how relaxation policies might affect
the transmission dynamics of SARS-CoV-2 is furthermore
hampered by the emergence of novel variants3,4 that have a
selective advantage, such as increased transmissibility5–8 or the
ability to reduce rapid neutralization by the host9. For example,
the current restrictions in Europe10 are in part caused by a more
transmissible5–8 and potentially more pathogenic11,12 B.1.1.7
variant that originated in the UK and is quickly gaining dom-
inance in other countries, including Portugal8,13,14.
The vaccines that have been approved in Europe15 show
consistently high efficacy against severe disease, hospitalization
and death in trials16–18 and show equally high effectiveness in
real-world settings19–23. Multiple studies are under way to
establish infection-blocking properties of these vaccines. Analyses
of the national vaccination programme in Israel indicate that the
effectiveness of the Pfizer-BioNTech vaccine against asympto-
matic SARS-CoV-2 infections could be as high as 94%22, as
announced recently by the Israel Ministry of Health, Pfizer Inc
and BioNTech SE. The recent Danish cohort study on long-term
care facility residents and healthcare workers further suggests that
the effectiveness of the Pfizer-BioNTech vaccine using a positive
PCR test as outcome measure is 64% and 90% beyond seven days
of second dose in the two groups, respectively20. Similar results
were found in a study among healthcare workers in England
where the effectiveness of the Pfizer-BioNTech vaccine against
symptomatic and asymptomatic infection was 86% seven days
after two doses23. Based on the data from Israel, the effectiveness
of the same vaccine against infection with SARS-CoV-2 was
shown to be 51% 13–24 days after one dose21. Finally, in a study
by Lipsitch and Kahn24, the lower bound for the efficacy against
transmission for one dose of Moderna vaccine was estimated at
61%, and could possibly be considerably higher, especially after
two doses.
The consequences of relaxing control measures such as phy-
sical distancing, school closure, mask-wearing, test-and-trace and
isolation, will depend on several factors, including the properties
of vaccines deployed in a given country, specifics of the vacci-
nation schedule, and speed of vaccine rollout, but also the past
epidemiology of SARS-CoV-2 that determines which fraction of
the population is protected by natural infection25,26. All these
factors are clearly country-dependent and will play a major role in
how the pandemic will unfold under different relaxation
scenarios27–30 and how quickly the full control of COVID-19 will
be gained in specific countries throughout 2021 and possibly
beyond. To make a few distinctive examples, we recall Israel
which has the highest vaccination rate worldwide so that, on
average, every person has received at least one vaccine dose by
mid-March 20211 and Manaus in Brazil, where the levels of
protection by natural infection close to the theoretical herd
immunity threshold were achieved prior to the start of mass
vaccination31.
An extensive body of literature addresses the challenges of real-
time modeling the COVID-19 pandemic32. Mathematical trans-
mission models robustly calibrated to available data are among
the best tools available to provide input into the discussion on
the response to the COVID-19 pandemic33–43 and they will
continue to play an important role in making decisions
surrounding the relaxation of measures in 202127–30,44. Several
modeling studies provided support for the development of
COVID-19 vaccines and early planning of vaccination scenarios
and rollouts45–49. These models, however, assumed that a large
proportion of the population is vaccinated instantaneously or did
not focus on relaxation strategies. More recently, organized teams
of modeling experts supporting decision-makers over health
emergencies in China, Australia and the UK evaluated the
roadmap scenarios for relaxation of control measures in these
countries in light of ongoing mass vaccination27–29,50.
The present study makes a contribution towards better
understanding of when and which control measures can be
relaxed as mass vaccination programmes progress in 2021. We
take Portugal as a case study where good quality data for model
parameterization are available but, apart from efforts of genomic
surveillance51 and a recent study on the pre-vaccination
dynamics of COVID-1952, there are few dedicated COVID-19
modeling studies for informing policymaking in this country53.
Using an age-structured transmission model that has been fitted
in a Bayesian framework to the data from various sources (age-
specific hospitalizations and seroprevalence, social contact and
demographic data, national vaccination plan and vaccine rollout
data etc.), we investigate future pandemic trajectories under
several alternative relaxation scenarios throughout 2021. Among
the explored strategies are (i) lifting measures to the same extent
as in summer 2020 and (ii) later on in autumn 2020, (iii) the
complete lifting of measures, and (iv) combinations of (i), (ii) and
(iii). We evaluate the impact of each scenario on the epidemic
dynamics as quantified by projected hospital admissions, the
time-dependent effective reproduction number, population
immunization level due to natural infection and vaccination, and
the timing of reaching control of COVID-19 in Portugal. Finally,
we discuss the implications of our findings for the post-pandemic
dynamics of SARS-CoV-2.
Results
Model calibration. The model was fitted to age-stratified
COVID-19 hospitalization data in the period from 26 February
2020 till 15 January 2021 and cross-sectional age-stratified SARS-
CoV-2 seroprevalence data assessed from 21 May 2020 till 8 July
2020. The model reproduces well the age-specific hospital
admissions (Fig. 1) featuring (i) the first pandemic wave
(March–April 2020), (ii) relatively low epidemic activity
(May–August 2020), (iii) the second pandemic wave (September-
mid-December 2020), (iv) the third wave that started in mid-
December 2020 and was still ongoing on 15 January 202154. The
estimated hospitalization rates increase with age from 0.12 (95%
CrI 0.07–0.23) per year for children under 5 years of age to 14.24
(95% CrI 9.91–21.23) per year for persons above 80 years (Sup-
plementary Fig. 1). In agreement with other studies55,56, the
estimated susceptibility to SARS-CoV-2 increases with age
(Supplementary Fig. 2). The meaning of model parameters is
given in Supplementary Tables 1 and 5, and their estimates are
shown in Supplementary Figs. 1 and 2.
The model also reproduces well the age-specific and total
seroprevalence in the population (Fig. 2). The estimated age-
specific seroprevalence ranged between 1.77% (95% CrI
0.98–2.91%) for 1–10 years old children to 4.61% (95% CrI
3.47–5.91%) for 20–40 years old adults (Fig. 2a). The total
seroprevalence steadily increased with time reaching 19.37% (95%
CrI 14.82–24.57%) on 15 January 2021 (Fig. 2b).
Time-varying contact patterns and effective reproduction
number. We estimated how age-specific contact rates in the
population changed due to control measures as the pandemic
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developed. These contact rates denote the average number of
transmission-relevant contacts per day a person in a given age
category has with persons in other age categories. We further
calculated the time-dependent effective reproduction number,
Re(t), defined as the average number of secondary infections
caused by one infectious individual in the population with age-
specific contact patterns and age-specific seroprevalence at time t.
Re(t) < 1 signifies the control of the pandemic with possibly some
of control measures in place. The full control of COVID-19 is
achieved when Re(t) < 1 and the contact rates in the population
are restored to the pre-pandemic level.
Our findings are summarized in Fig. 3, where we show the total
daily hospitalizations (Fig. 3a), the average (over all ages) number
of daily contacts in the population (Fig. 3b) and Re(t) (Fig. 3c)
evaluated bi-weekly in the period from 26 February 2020 till 15
January 2021. The green vertical lines indicate the estimated mid-
point transitions in the age-specific contact rates (see Methods).
The pre-pandemic average number of daily contacts was 12.6.
The estimated basic reproduction number (in the absence of
control measures and with zero seroprevalence) was 2.20 (95%
CrI 1.97–2.56). The control measures introduced during the first
wave in spring 2020 reduced the number of contacts to 4.2 (95%
CrI 3.3–5.0) and Re to 0.69 (95% CrI 0.64–0.75). After some of
these measures were lifted, the number of contacts increased to
5.9 (95% CrI 5.1–6.6) and Re increased to almost 1 and stayed
nearly constant throughout summer 2020. At the start of the
second wave in autumn 2020 that followed the opening of schools
and the associated changes in the contact patterns of the rest of
the population, the average number of contacts further increased
to about 7.6 (95% CrI 6.7–8.3) and Re to 1.24 (95% CrI
1.21–1.28). The reinforcement of measures during the second
wave could only reduce Re to 0.89 (95% CrI 0.86–0.99) as
Fig. 1 Model fit to COVID-19 hospitalizations. The age-stratified daily hospital admission data are shown as red dots. The median trajectories estimated
from the model are shown as the black lines. The gray shaded regions correspond to 95% Bayesian prediction intervals based on 2000 parameter samples
from the posterior distribution. Hospital admissions were estimated for 10 age groups (see Methods). For presentation purposes, we grouped
hospitalizations for ages [0,5), [5,10), [10,20) into the group of [0,20), so only 8 age groups are shown in this figure.
Fig. 2 Model fit to SARS-CoV-2 seroprevalence. a Age-specific seroprevalence. The violin shapes represent the marginal posterior distribution of the age-
specific seroprevalence in the model. b Total seroprevalence. The black line and the gray shaded region show the median total seroprevalence and 95%
credible intervals. The uncertainty in the model is based on 2000 parameter samples from the posterior distribution. The data (dots - percentage
seroprevalence and error bars - 95% confidence intervals) in a and b are taken from the cross-sectional seroepidemiological survey (First National
Serological Survey) conducted after the first pandemic wave59 and supplied in the Mathematica notebook available in the GitHub repository, https://
github.com/lynxgav/COVID19-vaccination57. The total seroprevalence refers to population older than 1 year59.
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compared to Re of 0.69 after more severe measures introduced
during the first wave. Finally, the increased activity of the
population around Christmas and the New Year 2021 initiated
the third wave in January 2021.
Vaccination rollout. We implemented the rollout of vaccination
against SARS-CoV-2 as set out prior to the start of the vaccina-
tion campaign by the Directorate-General of Health — a division
of Portuguese Ministry of Health concerned with public health
(Table 1)57. The mass vaccination started on 27 December 2020,
is planned to proceed in three phases that will cover the whole
population of Portugal by 31 December 2021. In the model results
presented in the main text, we made several simplifying
assumptions regarding vaccination, i.e., 1) at most 90% of each
age group will be vaccinated (as supported by the survey con-
ducted between 23 January and 5 February 2021 on the will-
ingness to get vaccinated where the percentage of the Portuguese
residents who want to get vaccinated exceeds 95%58) except for
persons under 20 years of age (as supported by the current
guidelines on the ineligibility for vaccination of persons under 18
years of age); 2) the distributed vaccine is by BioNTech/Pfizer
brand (as supported by the recent ECDC vaccination data for
Portugal where 96% of vaccine doses distributed up until Feb-
ruary 21, 2021 are by BioNTech/Pfizer); 3) vaccination is modeled
as a single event that immediately confers protection equivalent
to two vaccine doses; 4) we considered an infection-blocking
vaccine and formulated optimistic assumptions for vaccine effi-
cacies in reducing infection, disease and severe disease; 5) there is
no waning of protection against (re-)infection after natural
infection and vaccination. More details of the vaccination model
are given in Methods. In the sensitivity analyses, we explored the
impact on hospitalizations of timings of different relaxation steps,
pessimistic assumptions for vaccine efficacies, infectivity of
breakthrough cases in vaccinated persons, behavior compensation
post-vaccination and the maximum age-specific coverage
decreasing with age.
We used the rollout schedule (Table 1) and data (Fig. 4a) on
the age distribution of morbidities among the Portuguese
residents and age distribution of prioritized vaccination categories
(e.g., healthcare workers, long-term care facilities staff and
residents etc.) to calculate age-specific vaccination rates (number
of persons in a given age group vaccinated per day) as the
vaccination programme progresses (Fig. 4b; see Supplementary
Fig. 3 for detailed information). The vaccination rate refers to
vaccination with two vaccine doses. The maximum vaccination
coverage of 90% is projected to be reached in the following order
(Fig. 5a): 80+ (29 June 2021), [60,80) (20 July–23 July 2021),
[50,60) (29 August 2021) and [20,50) (16 November 2021) (see
Supplementary Fig. 4 for absolute numbers of vaccinated
persons). The total coverage in the population will increase to
9%/38%/73% (maximum coverage) by 1 May/1 August/16
November 2021 (Fig. 4b). The vaccination rollout data based
on fully vaccinated persons for Portugal1 agree well with these
projections.
Scenarios for relaxation of control measures. To account for the
epidemiological situation in Portugal between mid-January and
mid-March 202154, we modeled the third wave of hospitalizations
that was curbed by the substantial reinforcement of measures
similar to those implemented during the first wave in spring 2020.
We also modeled an increase in the transmisibility of the virus
due to the rapid spread of B.1.1.7. variant in Portugal. The
situation in mid-March 2021 is then described by the average
number of daily contacts of 4.2, Re of 0.67 and the circulating
variant that is 50% more transmissible5–7 than the original var-
iant that was dominant in Portugal until December 2020.
Starting from this situation, we generated scenarios for
relaxation of control measures as follows (Fig. 6): Scenario 1)
lifting all measures so that contact rates in the population return
to the pre-pandemic level (average rate of 12.6 contacts/day);
Scenario 2) partial lifting of measures that increases contact rates
to the level of September–October 2020 (7.6 contacts/day);
Scenario 3) partial lifting of measures that increases contact rates
to the level of June–August 2020 (5.9 contacts/day). In
accordance with the plan of the Portuguese government to
alleviate some of the current measures in spring 2021 and to
make the scenarios comparable, we used the same mid-point (1
April 2021) and the same speed of transition between the contact
levels (10 days).
The comparative analysis of Scenarios 1, 2, and 3 is shown in
Fig. 6. The model predicts that lifting all measures (Scenario 1;
Fig. 6a–d) launches a fourth wave that is significantly larger than
the previous waves, resulting in 58,226 cumulative hospitaliza-
tions between 1 April 2021 and 1 January 2022 (Fig. 6a). Re
Fig. 3 Estimated contact rate and effective reproduction number. a Total
daily hospital admissions with COVID-19. b Average (over all ages) number
of daily contacts in the population. c Effective reproduction number, Re(t).
The average daily contacts and Re were evaluated once every two weeks.
The green vertical lines indicate the estimated mid-point transitions in the
age-specific contact rates. The red horizontal line denotes Re= 1. The
hospitalization data are shown as red dots. The black solid lines are the
median trajectories estimated from the model. The gray shaded regions
correspond to 95% credible intervals.
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increases sharply from 0.67 on 23 March 2021 to 2.03 two weeks
later (Fig. 6c) which is very close to the basic reproduction
number of 2.20 at the start of the pandemic. The full control over
COVID-19 is reached on 18 May 2021 when Re drops below 1
and the contact rates are the pre-pandemic level (Fig. 6b). At this
threshold, 60% of the population acquired protection after natural
infection and only 10% are protected after vaccination (Fig. 6d).
Relaxing measures according to Scenario 2 (Fig. 6e–h) initiates a
new pandemic wave too, albeit smaller in magnitude than
Scenario 1 (8975 hospitalizations between 1 April 2021 and 1
January 2022; Fig. 6e). In this case, Re becomes smaller than 1 on
29 June 2021 (Fig. 6g) but the measures have to be kept in place
(Fig. 6f) to control the spread. The increase of contact rates to the
level of June–August 2020 (Scenario 3; Fig. 6i–l), however, does
not lead to a significant rise in hospitalizations (1450 hospitaliza-
tions between 1 April and 1 January 2022; Fig. 6i) because Re
Table 1 The Portuguese vaccination plan.
Category Age (years) Vaccination period Persons
Phase 1 937,361
Healthcare workers (HCW) 20–65 27 Dec 2020–28 Feb 2021 199,708
Long-term care facilities (LTCF) 01 Jan 2021–28 Feb 2021 148,119
Residents 65+ 86,982
Staff 20–65 61,138
Risk Group 1 50+ 01 Feb 2021–30 Apr 2021 513,634
Cardiac insufficiency 207,571
Coronary heart disease 169,265
Renal insufficiency 8201
Chronic obstructive pulmonary disease (COPD) 128,597
First response professionals (FRP) (firemen, police, military etc.) 20−65 01 Feb 2021−30 Apr 2021 75,900
Phase 2 3,333,191
Persons with or without morbidities unvaccinated beforea 65+ 01 May 2021–31 Jul 2021 1,873,349




Chronic kidney disease 4222
Obesity 392,959
High blood pressure 632,547
Phase 3 6,529,448
Remaining persons (excluding children)b 20–65 01 Aug 2021–31 Dec 2021 6,529,448
Totala 10,800,000
aThe Portuguese vaccination plan as set out prior to the start of the vaccination campaign assumes that all persons in the population will be vaccinated with a two-dose vaccine schedule. In the model,
the maximum vaccination coverage in any age group is 90%.
bAccording to the current guidelines, persons under 18 years old are not eligible for vaccination. In the model, we assumed that the age group of 0–20 years old is not vaccinated.
Fig. 4 Vaccination rollout schedule. a Age distribution of vaccination categories. b Total vaccination rate (number of persons vaccinated per day, black
line) and proportions of vaccination rate attributable to ages [0,20) (blue), [20,60) (yellow) and 60+ (red). The gray vertical lines in b indicate the
starting dates for different vaccination phases (Table 1). The age-specific vaccination rates are given in Supplementary Fig. 3.
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stays below 1 (Fig. 6k) but, like in Scenario 2, the measures have
to continue until sufficient number of people acquire protection
by vaccination to relax them completely.
In addition, we explored Scenario 4 (Fig. 7) where measures are
relaxed in a step-wise manner so that contact rates first rise to the
level of June–August 2020 (Step 1, Scenario 3), then to the level of
September–October 2020 (Step 2, Scenario 2) and, finally, to the
pre-pandemic level (Step 3, Scenario 1) (Fig. 7b). The mid-points
of transitions were 1 April, 1 June and 1 October 2021 (blue
vertical lines in Fig. 7) and the relaxation speed of 10 days was
Fig. 5 Vaccination coverage during the vaccination rollout. a Age-specific coverage (percentage of vaccinated persons per age group). b Total vaccination
coverage (percentage of vaccinated persons in the population). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1).
The coverages for ages [20,30), [30,40), and [40,50) are equal (see Supplementary Fig. 4 for the absolute numbers of vaccinated persons). The coverage
for ages [0,20) is zero. The vaccination rollout data based on fully vaccinated persons1 are shown in b as red dots.
Fig. 6 Scenarios for relaxation of control measures. a–d Lifting all measures so that contact rates in the population return to the pre-pandemic level. e–h
Partial lifting of measures so that contact rates increase to the level of September–October 2020. i–l Partial lifting of measures so that contact rates
increase to the level of June–August 2020. The blue vertical lines indicate the mid-point of the transition (1 April 2020). The gray vertical lines indicate the
starting dates for different vaccination phases (Table 1). The red horizontal line denotes Re= 1. The hospitalization data are shown as red dots. The thick
solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals.
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used for all transitions. In this scenario, additional waves can be
prevented altogether and hospitalizations stay at the level
comparable to that in summer 2020 when the epidemic activity
was low (Fig. 7a). The number of hospitalizations in Scenario 4
is 2.2 times larger than in Scenario 3 (3194 vs 1450 from 1 April
2021 till 1 January 2022) and 2.8 times smaller than in Scenario
2 (3194 vs 8975 in the same time period) but the situation would
still seem manageable for the healthcare system because the
model does not predict sharp increases in hospital admissions.
Most importantly, unlike in Scenarios 2 and 3 where contact
rates stay reduced after 1 April 2021, the return to pre-pandemic
contact patterns in Scenario 4 is gradual and the complete lifting
of measures occurs on 1 October 2021 which would have
important socio-economic consequences. Interestingly, Step 2 (1
June) and Step 3 (1 October) increase Re above 1 (Fig. 7c)
leading to waves of infections (Supplementary Fig. 5) but a large
increase in hospitalizations is not observed because a substantial
proportion of the vulnerable population has been vaccinated
(Fig. 5). The full control of the pandemic (Re(t) < 1 and pre-
pandemic contact rates) is reached on 8 February 2022 (Fig. 7c)
when 36% of the population are protected after natural
infection, 48% after vaccination, and 17% stay unprotected
(Fig. 7d). This is drastically different from Scenario 1, where
the control was reached mainly due to protection through
natural infection (60%), and the minority was protected by
vaccination (10%).
We would like to stress that for demonstration purposes the
timings of Steps 2 and 3 in Scenario 4 have been intentionally
chosen so that the epidemic activity (i.e., the number of
hospital admissions) in 2021 is similar to that in summer 2020.
The premature relaxation of measures can still lead to new
waves of hospitalizations. We demonstrate this in Supplemen-
tary Fig. 6 where Step 3 occurs on 1 August instead of
1 October 2021. In this case, a large outbreak is observed from
August till December 2021 and the total number of hospita-
lizations is 3 times larger (9650 vs 3194 from 1 April 2021 till 1
January 2022) than if measures were completely lifted on 1
October 2021.
Similarly, the results presented for all scenarios are the most
optimistic in terms of projected hospitalizations and get worse for
a pessimistic set of vaccine efficacies. For Scenario 4 which is
probably the most realistic scenario for the future relaxation of
measures, the model predicts a new pandemic wave that
continues until summer 2022 resulting in a 7.3-fold increase in
hospitalizations (30,028 vs 4088 admissions between 1 April 2021
and 24 June 2022) for pessimistic assumptions about vaccine
efficacies (Supplementary Fig. 7 and Supplementary Table 2).
We have also explored the impact on hospitalizations of
behavior compensation post-vaccination by which we imply that
individuals return to pre-pandemic contact rates immediately
upon getting vaccinated (Supplementary Figs. 7, 8 and Supple-
mentary Table 2). Both in the presence and in the absence of
behavior compensation in Scenario 4, the number of break-
through cases after vaccination is relatively small (about 5–6% of
the total cumulative cases) for optimistic vaccine efficacies and is
comparable to the number of infections in the unvaccinated
population (about 42–46% of the total infections) for pessimistic
vaccine efficacies (Supplementary Fig. 8 and Supplementary
Table 2). Overall, the change in behavior of vaccinated persons
would have relatively little impact on cumulative hospital
admissions, i.e., an increase of 5% from 4088 to 4301 for
optimistic vaccine efficacies and an increase of 4% from 30,028 to
31,344 for pessimistic vaccine efficacies (Supplementary Fig. 7
and Supplementary Table 2). Therefore, the model projections for
hospital admissions depend more strongly on our assumptions
regarding pessimistic and optimistic vaccine efficacies (i.e., several
fold increase in hospitalizations for the range explored) and to a
smaller extent on the assumptions regarding behavioral changes
in the vaccinated population (i.e., few percent increase in
hospitalizations for the range explored). These findings are
sensitive to the infectivity of breakthrough cases in vaccinated
persons (Supplementary Fig. 11 and Supplementary Table 6). In
Fig. 7 Sequential relaxation of control measures. This scenario consists of sequential relaxation of measures so that the contact rates increase, in
sequence, to the level of June–August 2020, of September–October 2020 and the pre-pandemic level. The blue vertical lines indicate the mid-points of
these transitions (1 April, 1 June, 1 October). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1). The red horizontal
line denotes Re= 1. The hospitalization data are shown as red dots. The thick solid lines are the median trajectories estimated from the model. The gray
shaded regions correspond to 95% credible intervals.
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particular, for a vaccine that is highly effective in reducing
susceptibility (94% under our optimistic assumptions), the impact
of infectivity of vaccinated persons on hospitalizations is small
(a 15% decrease from 4088 to 3492 admissions in a hypothetical
best-case scenario of zero infectivity in Scenario 4; Supplementary
Table 6). For a vaccine with a low efficacy in reducing
susceptibility (55% under our pessimistic assumptions), the
impact on hospitalizations is much larger (a 77% decrease from
30,038 to 6410 admissions for the same scenario; Supplementary
Table 6).
Finally, our results are also dependent on the assumed
maximum coverage of 90% in all age groups. In reality, as
vaccination coverage in older age groups will start to saturate,
younger people might have lower intent to get vaccinated. The
sensitivity analyses for the maximum coverage decreasing with age
(90% in 80+, 85% in [50,80), 75% in [20,50) and 0% in [0,20)
years old; Supplementary Figs. 8 and 9) show that the cumulative
median number of hospitalizations from 1 April 2021 till 1
January 2022 for Scenarios 1, 2 and 3 would be almost equal to the
situation when the maximum vaccination coverage is independent
of age and very high (Figs. 5 and 6). For Scenario 4, the number of
hospitalizations would be 8% higher than in Fig. 6. The reason for
this is that in Scenario 1 the pandemic unfolds much faster than
vaccination is rolled out. In Scenarios 2 and 3 the pandemic is
partially controlled through the measures, i.e., the contact rates
continue to be reduced till the end of 2021. In Scenario 4, though,
the contact rates return to the pre-pandemic levels on 1 October
2021 while the coverage is not sufficiently high leading to a slight
increase in hospitalizations at the end of 2021.
Discussion
In this study, we used an age-structured model for SARS-CoV-2
transmission to generate and evaluate scenarios for relaxation of
control measures during the ongoing vaccination rollout in
Portugal. In agreement with the plans of the Portuguese gov-
ernment, the mid-point of easing of measures is April 2021. Our
analyses demonstrate that vaccination alone, if rolled out
according to the national vaccination schedule, is likely to be
insufficient to control the Portuguese pandemic in case control
measures are significantly alleviated already in April 2021. In fact,
in our analyses returning to the pre-pandemic lifestyle already in
spring 2021 is a worst-case scenario that would likely lead to
overburdening of the heatlhcare system. Even for the most
optimistic model assumptions, this scenario would result in a
wave of hospitalizations 20% larger than the three previous waves
combined together (58,226 cumulative median hospitalizations
from 1 April 2021 till 1 January 2022 versus 48,273 hospitaliza-
tions from 25 February 2020 till 31 March 2021). Relaxing
measures to the same extent as in autumn 2020 would lead to a
smaller wave (as compared to the worst-case scenario and even to
the third wave that actually occurred) that would, nonetheless,
present a significant burden for the healthcare system. Our
findings are qualitatively similar to those in modeling studies for
China29 and the UK27,28. However, a quantitative comparison is
not possible because of different settings and contexts in which
these studies were conducted. Additional waves could be pre-
vented altogether if measures in spring 2021 are relaxed to the
same extent as in summer 2020 or in a step-wise manner
throughout 2021.
The point at which the pandemic is brought under full control
(Re(t) < 1 and pre-pandemic contact patterns) depends on the
amount of protection in the population acquired through a
combination of natural infection and vaccination. Gaining the
control quickly (by mid-May 2021) occurs mainly through
protection by natural infection (60% of the population) while the
minority (10%) would be protected by vaccination. As mentioned
above, this worst-case scenario is, obviously, undesirable and is
not very much different from letting the pandemic develop
without any control measures. In the gradual relaxation scenario,
achieving control takes more than one year since the start of
vaccination rollout, but almost 50% of the population are pro-
tected by vaccination and a smaller proportion (35%) have
experienced SARS-CoV-2 by that point. Alternative to these
scenarios would be accelerating the vaccination campaign so that
vaccination coverage increases faster than initially projected and
confirmed by the vaccination rollout data1. However, it is not
clear whether this option is viable for Portugal given the current
shortage for COVID-19 vaccines.
In comparison with the previous studies27–29, a strength of our
analyses is that we calculate the effective reproduction number
using the estimated current levels of age-specific seroprevalence
and vaccination coverage in the population instead of reducing
the value of Re at the beginning of the pandemic homogeneously
across age groups. Another strength of our analyses is that, unlike
earlier studies for China and the UK27–29, the parameters of our
model are based on formal statistical inference to match the
course of the Portuguese pandemic as reflected by age-specific
hospital admissions and age-specific seroprevalence data59. In
addition, our fitting procedure allows for estimation of temporal
changes in age-dependent contact patterns as a response to prior
control measures during this pandemic. Therefore, instead of
modeling specific relaxation policies that are not straightforward
to implement in a compartmental model like ours (e.g., increased
contact tracing33) or other policies in which governments might
be interested but that do not have immediate interpretation in
terms of (setting-specific) contact matrices (e.g., banned gather-
ings of more than 3 people and family members of COVID-19
patients have to stay at home or allowing a visitor per 25 square
meters of space in a shopping area without prior appointment),
we model several scenarios using the estimated contact structure
after relaxation of measures in summer and autumn 2020.
In light of these past measures, our findings are easy to
interpret and contain an important message for local policy-
makers. School opening is thought to be the main driver of the
changes observed in autumn 2020, although an increase in
socializing indoors in general caused by weather alone must also
have played a role. If the relaxation planned for April 2021
includes school reopening in full after Easter and resuming
indoor service in restaurants and bars, then it is very likely that
the average contact rate in the population will reach levels very
similar to those in autumn 2020. As a consequence, this might
lead to a new wave of hospitalizations as illustrated in Scenario 2.
On the bright side, according to our analysis the goal of Scenario
3, in which major waves are avoided, seems well within reach,
given the light control measures that were in place during sum-
mer 2020. Combining these with some additional limitations of
indoor social activities and online classes for secondary school
students could help to replicate the average contact rate of
summer 2020, compensating for opening of elementary schools.
As any model, our model has limitations. An important one is
that protection against (re-)infection after natural infection and
vaccination is permanent over the time-scale of our analyses
(almost two years). This frequently used assumption27–29,45,48
leads to that in our model, theoretically, SARS-CoV-2 can be
eliminated from the population. However, as we discussed
recently60 and as addressed in several conceptual modeling
studies61–63, accumulating evidence suggests that after the initial
pandemic phase SARS-CoV-2 is likely to be transitioning to
endemicity and continued circulation. Specifically, recent data
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from individual-level studies point to that detectable levels of
antibodies to SARS-CoV-2 providing immunity against reinfec-
tion can wane on the time scale of a few months to few years
following exposure, as shown by our group64 and corroborated
with findings of other studies65–67. However, the immunity to
SARS-CoV-2 depending on a combination of B- and T-cell-
mediated responses elicited during primary SARS-CoV-2 infection
could reduce susceptibility to and infectiousness of the following
infections and offer protection against severe disease, i.e., COVID-
1968. The estimation of the model parameters and evaluation of
relaxation strategies in light of waning of sterilizing immunity lies
outside the scope of our study but it should be addressed in future
work when convincing data on reinfections in unvaccinated and
vaccinated individuals become available.
Another limitation that deserves mention is that our results
are based on early data on the efficacy in clinical trials and real-
world effectiveness of the Pfizer-BioNTech vaccine16,19–23. We
also assume that vaccine efficacy against the B.1.1.7 variant
circulating in Portugal is the same as the efficacy reported from
studies conducted in other locations, e.g., the recent study
among working age adults in England23, where the dominant
variant in circulation was B.1.1.7. This study demonstrated that
effectiveness of the Pfizer-BioNTech vaccine against sympto-
matic and asymptomatic infection is 86% seven days after two
doses23. However, SARS-CoV-2 mass vaccination programmes
and prolonged control measures can generate selection pressure
leading to viral adaptation, antigenic divergence or vaccine
escape. Viral adaptations may contribute to decreasing efficacy
of existing vaccines via faster waning of (sterilizing) immunity.
For example, recent experiments demonstrate that the South
African variant B.1.351 shows reduced neutralizing antibody
binding increasing the prospects of reinfection and hampering
the efficacy of spike-based vaccines69. This will need con-
sideration in vaccine development and evaluation of future
vaccination programmes and relaxation scenarios in mathe-
matical transmission models. A possible case where an anti-
genic escape variant caused a resurgence of COVID-19 despite
high population-level seroprevalence was observed in Manaus,
Brazil31. In Portugal, the P.1 (Brazilian) variant of concern
associated with the outbreak in Manaus does not appear to be
on the rise by the end of March 2021. Should this variant start
to spread later during 2021, the relaxation scenarios performed
for pessimistic vaccine efficacies would be more appropriate in
accordance with recent experimental studies demonstrating
that the P.1 variant may evade neutralizing antibody responses
induced by infection and vaccination70.
Lastly, our analyses assume a causal relation between the
control measures and the reduction in circulation of SARS-
CoV-2, and do not incorporate seasonal variation in trans-
missibility. The data on human coronaviruses (229E, HKU1,
NL63, OC43) from other locations (e.g., New York or Stock-
holm) show a marked seasonal pattern61,62,71 with hardly any
circulation in summer. If the seasonality played a major role in
transmission of SARS-CoV-2 in summer 2020 then, irrespec-
tive of the relaxation of control measures, we could expect low
epidemic activity near the end of spring 2021 too. The sea-
sonality would also imply that the effective reproduction
number is higher during the winter season and lower during
the summer season, and could explain a relatively low basic
reproduction number (median value of 2.20) estimated by the
model in March 2020, although this value lies within the range
of published estimates for other countries72.
To summarize, our study provides timely input into the dis-
cussion about the pandemic response during the vaccination
rollout in Portugal. Our analyses suggest that the pressing need to
restart socioeconomic activities might lead to new waves of
hospitalizations in 2021 and that substantial measures prove
necessary to control COVID-19 throughout 2021. More favorable
scenarios that help to avoid future waves include relaxation of
measures as in summer 2020 or a step-wise approach when
measures are relaxed gradually until the end of 2021.
Methods
Overview. The transmission model was calibrated using a combination of beha-
vioral, surveillance and demographic data for Portugal. Parameter estimates were
obtained from the model fit to (i) age-stratified COVID-19 hospitalization data
(n= 28,482) in the period from 26 February 2020 till 15 January 2021 and (ii)
cross-sectional age-stratified SARS-CoV-2 seroprevalence data (n= 2301) assessed
from 21 May 2020 till 8 July 202059. The model was further used to investigate
relaxation scenarios as vaccination is rolled out in 2021.
Data. The hospitalization data included n= 28,482 COVID-19 hospitalizations
longer than 24 hours by date of admission and stratified by age during the period of
325 days following the first official case in Portugal (2 March 2020). The data was
padded with 5 days without hospitalizations (from 26 February till 1 March 2020)
to allow for the estimation of the number of infected individuals at the start of the
pandemic. The hospitalization data spanned the first wave in spring 2020, relatively
low epidemic activity in summer 2020, the second wave that started in autumn
2020 till mid-December 2020 and the third wave that started in mid-December
2020 and was still ongoing on 15 January 2021. The data source for hospital data
was the Central Administration of the Health System and the Shared Services of the
Ministry of Health, covering all public hospitals in Portugal receiving COVID-19
patients. Since early in the pandemic, Portugal adopted a policy of hospitalizing
only patients who did not gather minimum conditions for being followed at the
domicile, either due to clinical or sanitary conditions. This policy has not changed
during the course of the pandemic.
The SARS-CoV-2 seroprevalence data was based on the First National
Serological Survey (ISNCOVID-19) in Portugal in May/July 202059. This cross-
sectional seroepidemiological survey was conducted on a sample of n= 2301
Portuguese residents, aged 1 year or older, after the first wave. The survey sample
was selected using a two-stage stratified non-probability sampling design (quota
sampling)59. SARS-CoV-2 IgM and IgG antibodies were measured in serum
samples by enzyme-linked immunosorbent assay. Further details of the study are
given in59. For the model fitting, we used the sample size, the number of positive
samples and 95% confidence intervals stratified by age group reported in59.
The demographic composition of the Portuguese residents was taken for 2019
from the Contemporary Portugal Database (Pordata)73. The vaccination analyses
made use of the vaccination programme (Table 1), as defined by the Directorate-
General of Health prior to the start of the vaccination campaign54. The programme
defines vaccine uptake prioritization by age and morbidities and runs in three
phases from 27 December 2020 till 31 December 2021. The age distribution of
morbidities in the Portuguese population was extracted from the Shared Services of
the Ministry of Health on the basis of ICPC-2 (International Classification of
Primary Care) codes (Supplementary Table 3). The vaccination rollout data for
Portugal was taken from1.
The baseline (pre-pandemic) contact matrices for transmission-relevant
contacts for Portugal were taken from the recent study by Mistry et al.74. The
contact matrix for Portugal after the introduction of measures to control the first
wave of hospitalizations (April 2020) was inferred using the contact matrix for the
Netherlands based on a cross-sectional survey carried out in April 2020 (PIENTER
Corona study)75.
Transmission model. We extended an age-stratified SARS-CoV-2 transmission
model from43 to include vaccination (Fig. 8). The model has susceptible-exposed-
infectious-recovered structure, whereby susceptible persons (S) may become
latently infected (E) before progressing to become infectious (I). The latently
infected persons are infected with SARS-CoV-2 but not yet infectious. Persons
enter the I-compartment when they become infectious independently of whether
they have symptoms or not. Therefore, this compartment contains both sympto-
matic and asymptomatic individuals. The stratification in these two categories is
not done because the parameters of the model would not be identified from the
model fit to the data streams we used. Note that in our previous model43, we split
the infectious period into several stages, thereby obtaining a more realistic dis-
tribution of the infectious period (i.e., Erlang/Gamma distribution instead of an
exponential distribution used here). For computational reasons (much longer time
series and more complex projections) we do not implement an Erlang-distributed
infectious period this time. Infectious persons either get hospitalized (H) or recover
without hospitalization (R). Disease-related mortality and discharge from the
hospital are not explicitly modeled. Therefore, the H-compartment contains the
cumulative number of persons who experience severe symptoms and recover (or
die) after admission to the hospital. Similarly, the R-compartment contains the
cumulative number of persons who recover after having mild or no symptoms. The
force of infection is given by a weighted sum of the fraction of the infectious
population in different age groups (red dashed boxes in Fig. 8). We consider a
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stable population and thus do not include natural birth and death processes. The
contact rates, forces of infection, susceptibilities and hospitalization rates are age-
specific.
In line with the current guidelines, we assume that vaccine can be delivered to
all people independently from their disease history with the exception of those who
might be currently infectious (I-compartment). Not vaccinating infectious
compartment implies that vaccine is not given to asymptomatic persons but these
represent a small fraction of the population at any given time as the absolute
majority of the population is either in susceptible (S-compartment) or in recovered
states (H and R-compartments). We also vaccinate the H-compartment as this
compartment comprises everyone who has ever been admitted to hospital. Whilst
this assumption means that the currently hospitalized persons are vaccinated too,
their number is very small compared to the total number of people in the H-
compartment. The vaccine has three mechanisms of action: (i) reducing
susceptibility (VES); (ii) reducing infectivity (VEI); (iii) reducing hospitalization
rate (VEH). The vaccine has no effect in persons who recovered from natural
infection (R and H compartments). We assume that protection after vaccination is
achieved immediately and is equivalent to two vaccine doses, and that the duration
of protection after both natural infection and vaccination is about two years (time
horizon of our analyses). Finally, we allow for behavior compensation post-
vaccination modeled as a return to pre-pandemic contact rates among vaccinated
persons as compared to unvaccinated persons who may continue to have reduced
contact rates due to control measures. This is reflected in generally different forces
of infection for unvaccinated and vaccinated persons. The full description of the
model parameters is given in Supplementary Tables 1 and 5.
Model equations. The model was implemented in Mathematica 10.0.2.0 using a
system of ordinary differential equations for the number of persons in different
compartments shown in Fig. 1. The transmission model was stratified into n= 10
age groups: [0, 5), [5, 10), [10, 20), [20, 30), [30, 40), [40, 50), [50, 60), [60, 70),
[70, 80), 80+.
The equations for the numbers of unvaccinated persons in age group k, k= 1,
…, n, who are susceptible (Sk), exposed (Ek), infectious (Ik), recovered (Rk) and









¼ βkλkðtÞSkðtÞ  αEkðtÞ 
rkEkðtÞ















SkðtÞ þ EkðtÞ þ RkðtÞ þHkðtÞ
:
ð1Þ
The equations for the numbers of vaccinated persons in age group k who are
vaccinated susceptible (SVk ), exposed (E
V
k ), infectious (I
V
k ), recovered (R
V
k ) and
hospitalized (HVk ) are given by
dSVk ðtÞ
dt
¼ βkð1 VESÞλVk ðtÞSVk ðtÞ þ
rkSkðtÞ




¼ βkð1 VESÞλVk ðtÞSVk ðtÞ  αEVk ðtÞ þ
rkEkðtÞ









¼ γIVk ðtÞ þ
rkRkðtÞ




¼ νkð1 VEH ÞIVk ðtÞ þ
rkHkðtÞ
SkðtÞ þ EkðtÞ þ RkðtÞ þ HkðtÞ
:
ð2Þ
Persons get vaccinated in S, E, R and H states. The vaccination rates rk are age-
specific. We denote the contact rate of an unvaccinated person in age group k with
persons in age group l, ckl(t), and the contact rate of a vaccinated person in age
group k with persons in age group l, cVklðtÞ. The forces of infection for unvaccinated
and vaccinated persons are given by




IlðtÞ þ ð1 VEI ÞIVl ðtÞ
Nl
; ð3Þ




IlðtÞ þ ð1 VEI ÞIVl ðtÞ
Nl
; ð4Þ
where Nk is the number of individuals in age group k, Nk ¼ SkðtÞ þ EkðtÞ þ IkðtÞþ
HkðtÞ þ RkðtÞ þ SVk ðtÞ þ EVk ðtÞ þ IVk ðtÞ þ RVk ðtÞ þHVk ðtÞ. Note that Eqs. (3) and (4)
imply that the entire population participates in the contact process including
persons in the H-compartment but that H-persons are not infectious. This is based
on the fact that the vast majority of people in the H-compartment are recovered
after hospitalization, and a very small proportion is currently hospitalized. We
assume that currently hospitalized persons continue to have contacts with the
personnel and visitors but they cannot infect them because of the use of individual
protective measures.
The initial condition for the model was Ekðt ¼ 0Þ ¼ Ikðt ¼ 0Þ ¼ 12 θNk and
Sk(t= 0)= (1− θ)Nk, where t= 0 is 26 February 2020. The parameter θ denotes the
initial fraction of the population that was infected (split equally between infectious and
exposed). This parameter accounts for importation of new cases at the start of the
pandemic and was estimated jointly with other parameters. Importation of cases was
not implemented at later stages of the pandemic due to a large pool of infectious
individuals within the country.
The rapid spread of B.1.1.7 variant, that is estimated to be about 50% more
transmissible based on the data from England5–7, fueled the third wave of
hospitalizations in Portugal. The increasing dominance of this variant was modeled
empirically as a gradual increase in the probably of transmission per contact by
50% as follows ϵ½1þ 0:5=ð1þ eK0ðttdata ÞÞ, where ϵ and K0 were estimated based
on the data until 15 January 2021 (Supplementary Fig. 2) and tdata is the last date in
the hospital admission data (15 January 2021).
Observation model and parameter estimation. To generate a set of plausible
parameters and initial conditions for our projections, we fitted the model to
Fig. 8 Schematic of the transmission model. Gray arrows show epidemiological transitions. Red dashed boxes indicate compartments contributing to the
forces of infection. The model is age-structured and involves an extended SEIR-type framework. Vaccinated persons may experience behavior
compensation post-vaccination modeled as a return to pre-pandemic contact rates among vaccinated persons as compared to unvaccinated persons who
may continue to have reduced contact rates due to control measures. The vaccine has three effects: (i) reduction in susceptibility of vaccinated relative to
unvaccinated (VES); (ii) reduction in infectivity of vaccinated relative to unvaccinated (VEI, see Eqs. (3) and (4)); (iii) reduction in hospitalization rate of
vaccinated relative to unvaccinated (VEH).
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hospitalization data and serological testing data, using a similar approach as
before43,76. We incorporated the transmission model, Eq. (1), in a Bayesian sta-
tistical model with likelihood function constructed as follows. Let hk,m denote the
observed number of hospitalizations in age group k and day tm. The expected
number of hospitalizations during day tm is approximately equal to
hk;m :¼ νk  IkðtmÞ. To account for reporting errors and heterogeneity in the hos-
pitalization rate within age groups, we assume that hk,m has a negative-binomial
distribution with mean hk;m and variance hk;m  ð1þ hk;m=ϕÞ. The parameter ϕ
determines the overdispersion of the reporting of hospitalizations. The hospitali-
zation data were stratified into the ten age groups [0, 5), [5, 10), [10, 20), [20, 30),
[30, 40), [40, 50), [50, 60), [60, 70), [70, 80), 80+.
The seroprevalence data were stratified into the five age groups [1, 10), [10, 20),
[20, 40), [40, 60) and 60+59. Hence, for the hospitalization data and the
transmission model, a finer age stratification is used than for the seroprevalence
data. We assume that individuals in seroprevalence age group Gsi were sampled
from hospitalization age class Ghk with probability pik proportional to the relative
population size of Ghk compared to G
s
i , i.e.,
pik ¼ Nk=Nsi ; where Nsi ¼ ∑
‘:Gh‘Gsi
N‘: ð5Þ
As before43, we assume that the seroprevalence data represents a random
sample from each age group. Hence, the number of positive samples ℓi has a
binomial distribution with population size Li, equal to the total number of samples
for age class i, and success probability qi. The success probability is defined in terms





To account for the fact that no children below the age of 1 year were included in
the serology samples, we reduced the population size N1 with the size of the age
group [0, 1) (86,579 persons) in Eqs. (6) and (5).
The prior distribution of the model is specified in Supplementary Table 4.
Informative priors were used for the latent (1/α) and infectious (1/γ) periods. Our
choice of the range for the prior for the latent period (time between infection and
becoming infectious) was based on the estimates of 4–6 days for the incubation
period (time between infection and developing symptoms)72,77. Since the current
evidence suggests that SARS-CoV-2 transmission is possible before the development
of symptoms, the latent period was chosen to be shorter than the incubation period,
i.e., we used a narrower range of 2–5 days for 99% of the prior density of the latent
period. The average generation interval in the model is 1/α+ 1/γ. The priors on α
and γ were chosen to match observed generation intervals (more precisely the serial
interval78) of on average 7 to 8 days. Also note that the effective infectious period
has likely decreased because (self-)isolation upon the development of respiratory
symptoms has been recommended and, in certain situations, enforced (e.g., at
schools, hospitals) during the course of the pandemic78. Contact tracing and testing
of asymptomatic persons also decreases the time of infectiousness. The mean a
priori generation interval was 7.3 days (99% CrI 5.5–9.3). The individual serial
intervals and duration of the infection have a much wider distribution.
The model was fitted with Stan79 in R 3.6.0 and R Studio 1.3.1056 using
cmdstanr package. We used 4 parallel chains, each of length 1000, with a warm-up
period of 500, resulting in 2000 samples from the posterior distribution.
Convergence was assessed with the Gelman-Rubin R̂-statistic, which was close to 1
for all parameters.
The estimated model parameters are shown in Supplementary Figs. 1 and 2. As
in our previous work43 (Supplementary Fig. 5 therein), some of the parameters
such as e.g., the infectious period, the initial fraction of infected individuals, the
probability of transmission per contact and the hospitalization rate are strongly
positively and negatively correlated. However, the outcomes of the model such as
the cumulative number of hospitalizations during the study period are not sensitive
to the key epidemiological parameters among which the infectious period, the
latent period and the probability of transmission per contact. See scatter plots in
Supplementary Fig. 12 made for Scenario 4 and a pessimistic set of vaccine
efficacies where Pearson correlation coefficients between the three parameters and
cumulative hospitalizations from 25 February 2020 till 24 June 2022 are in the
range of 0.09 to 0.14.
Time-varying contact patterns. The contact patterns in the population varied
with time due to introduction/reinforcement or relaxation of control measures as
follows: 0) introduction of measures to control the first pandemic wave (first
lockdown, March 2020); 1) relaxation of measures after the first wave was curbed
(May 2020); 2) further relaxation of measures that included school opening
(September 2020); 3) reinforcement of measures to control the second wave
(second lockdown, November 2020); 4) relaxation of measures around Christmas
2020; 5) reinforcement of measures to control the third wave (third lockdown,
January 2021).
We denote ckl(t) the contact rate for a person in age group k (k= 1,…, n) with
persons in age group l (l= 1,…, n) at time t. The contact rate denotes the number
of transmission-relevant contacts per day such as touching or having a
conversation with someone74,75. Our fitting procedure allows to estimate ckl(t) by
assuming that changes due to control measures described in 0)-5) occur as a series
of smooth transitions.
To describe the transition 0) from the baseline (pre-pandemic) contact rate bkl
to the contact rate after the first lockdown akl we write down ckl(t) as a linear
combination of contact rates bkl and akl with coefficients constructed using a
logistic function f 0ðtÞ ¼ 1= 1þ eK0 ðtt0Þ
 
as follows
cklðtÞ ¼ ½1 f 0ðtÞbkl þ f 0ðtÞζakl : ð7Þ
The parameter K0 of the logistic function describes the speed with which the first
lockdown is enforced. The parameter t0 describes the mid-time of the introduction
of the first lockdown. Note in Eq. (7) we introduced the factor ζ∈ [0, 1] to reflect
that not all reported contacts after the first lockdown might be relevant for
transmission, for example, due to mask-wearing or physical distancing when a
contact took place. Therefore, the baseline (pre-pandemic) contact rates are
described by the matrix bkl, and the contact rates after the first lockdown are
described by the matrix ζakl.
The pre-pandemic matrix bkl for Portugal was taken from74 (Fig. 9a). The
matrix after the first lockdown akl was inferred using the contact matrix for the
Netherlands based on a cross-sectional survey carried out in April 2020 (PIENTER
Corona study)75. Since measures enforced during the first lockdown in the two
countries were similar (e.g., all schools were closed, all non-essential work was done
from home etc.) we reduced the age-specific contact rates for Portugal after the
lockdown by the same percentage as it was observed in the Netherlands (Fig. 9b).
The resulting number of daily contacts for a person in given age group at baseline
and after the lockdown in April 2020 is shown in Fig. 9c. Like for the
Netherlands75, we observe larger reductions in contacts for children (due to school
closure) and smaller reductions for elderly because most of their contacts were
essential (e.g., with healthcare personnel or caretakers) and thus were not affected
by the lockdown. The parameter ζ that multiplies the inferred matrix akl can
account for discrepancies between the real and inferred matrix.
To describe the contact rates after transitions 1)-4) have taken place, we
assume that these can be written as a linear combination uibkl+ (1− ui)ζakl, i=
1,…, 4, where ui is the proportion of time a person behaves as before the
pandemic and (1− ui) is, respectively, the proportion of time a person behaves
as during the first lockdown. This contact structure can, therefore, interpolate
between the first (most strict) lockdown and no measures in place at all. Since
the third lockdown was similar to the first lockdown, the transition 5) was
modeled as a return to the lockdown contact matrix ζbkl. As before, the
transitions between the contact rates during periods 1)-5) are modeled using
logistic functions f iðtÞ ¼ 1= 1þ eKiðttiÞ
 
, where i= 1,…, 5. The general
contact rate can therefore be written as
cklðtÞ ¼ ½1 f 0ðtÞbkl þ f 0ðtÞζakl½1 f 1ðtÞ þ f 1ðtÞ½u1bkl þ ð1 u1Þζakl ½1 f 2ðtÞ
þ f 2ðtÞ½u2bkl þ ð1 u2Þζakl ½1 f 3ðtÞ þ f 3ðtÞ½u3bkl þ ð1 u3Þζakl½1 f 4ðtÞ
þ f 4ðtÞ½u4bkl þ ð1 u4Þζakl ½1 f 5ðtÞ þ f 5ðtÞζakl :
ð8Þ
All the parameters that describe ckl(t), except for the last transition 5) for which
hospitalization data are not available, are estimated (Supplementary Table 5).
The estimates for these 15 parameters ζ, ui (i= 1,…, 4), ti (i= 0,…, 4) and Ki
(i= 0,…, 4) are shown in Supplementary Fig. 2. The estimated logistic functions
are plotted in Fig. 9d.
In the main analyses (Figs. 6 and 7), the contact rates for vaccinated persons
were equal to those unvaccinated, cVklðtÞ ¼ cklðtÞ. In the sensitivity analyses
(Supplementary Figs. 7, 8 and Supplementary Table 2), they were set to pre-
pandemic contacts as follows, cVklðtÞ ¼ bkl . The contact rate presented in Figs. 3, 6
and 7 was the average contact rate in the population calculated as follows
hcðtÞi ¼ ∑nk¼1 ∑nl¼1 cklðtÞNk=∑nk¼1 Nk . Note that this expression makes use of the
fact that in the main analyses cVklðtÞ ¼ cklðtÞ.
The relaxation scenarios during the vaccination rollout are modeled as a
transition from the contact rate described by Eq. (8) to the contact rate bkl
(Scenario 1); u2bkl+ (1− u2)ζakl (Scenario 2); u1bkl+ (1− u1)ζakl (Scenario 3);
u1bkl+ (1− u1)ζakl (Scenario 4, Step 1); u2bkl+ (1− u2)ζakl (Scenario 4, Step 2); bkl
(Scenario 4, Step 3). The parameters of the logistic functions describing these
transitions are specified in Supplementary Table 5.
Time-varying effective reproduction number. The basic reproduction number,
R0, is the average number of secondary infections caused by a single infectious
individual at the beginning of the epidemic in a disease-free, totally susceptible
population. If R0 > 1 the disease will spread exponentially. If R0 < 1 the number of
infectious persons declines exponentially and the disease is not able to spread. In
general, R0 depends on the type of virus but also on the contact patterns in the
population.
When the disease has already spread and we have no longer a fully susceptible
population but some part of the population is immune due to natural infection or
vaccination, the generalization of R0 is given by the effective reproduction number,
Re(t). Re(t) depends on the type of virus, the level of population immunity and the
contact patterns in the population. The full control of the disease is achieved when
Re(t) < 1 and the contact rates in the population are at their pre-pandemic levels,
i.e., not anymore affected by control measures. A partial control is achieved when
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Re(t) < 1 but the contact rates have not been restored to their pre-pandemic levels
yet as is currently the case for SARS-CoV-2 in Portugal.
In a deterministic compartmental model such as the one employed here, the
calculation of R0 and Re(t) can be performed using the next-generation matrix
(NGM) method80. The starting point of the method is to calculate the Jacobian J of
the equations for the latent (Ek, EVk ) and infectious (Ik, I
V
k ) age classes k, k= 1,…,
n, isolated from the full model given by Eqs. (1) and (2). The Jacobian J is then
evaluated at the disease-free equilibrium of interest.
For R0 calculation, the disease-free equilibrium is
Sk
 ¼ Nk; SVk
 ¼ Ek ¼ EVk
 ¼ Ik ¼ IVk
 ¼ 0; k ¼ 1; ¼ ; n: ð9Þ
For Re(t) calculation with or without vaccination, the disease-free equilibrium is
Sk
 ¼ SkðtÞ; SVk
 ¼ SVk ðtÞ; Ek ¼ EVk
 ¼ Ik ¼ IVk
 ¼ 0; rk ¼ 0; k ¼ 1; ¼ ; n;
ð10Þ
where the time-dependent variables Sk(t) and S
V
k ðtÞ are obtained from the solutions
of the full model given by Eqs. (1) and (2).
Following80, the Jacobian J may be recast as follows
J ¼ Tþ Σ; ð11Þ
where the transmissions matrix T contains the terms associated with the
Fig. 9 Contact matrices. a Baseline (pre-pandemic) contact matrix. b Contact matrix after the introduction of measures in April 2020. c Average number of
contacts for a person in a given age group. d Logistic functions describing transitions between contact matrices. Shown are f0 (blue), f1 (dark green), f2
(light green), f3 (orange), and f4 (red) based on 50 samples from the posterior distribution.
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production of new infections, and the transitions matrix Σ contains the terms
associated with all other state changes. After performing this operation, we
construct a new matrix KL, called the large domain NGM80, given by
KL ¼ TΣ1: ð12Þ
The basic reproduction number R0 at time t= 0 and the effective reproduction
number Re(t) at any time t are given by the spectral radius of KL which is the largest
eigenvalue of KL. For the purpose of computing the spectral radius, KL can be
further reduced as detailed in80. The explicit expressions for matrices J, T, Σ and KL
are given in the Mathematica notebooks available in the GitHub repository, https://
github.com/lynxgav/COVID19-vaccination57.
Population immunity. The unprotected population was computed as the number
of individuals in the fully susceptible compartment S (Fig. 8). The population
protected by natural infection was computed as all individuals arriving into the
infectious compartment I, independently of whether these individuals will or will
not be vaccinated later on. Recall, that in the model vaccine has no effect in
individuals who are recovered from natural infection and, therefore, the population
protected by vaccination grows slower than vaccination coverage. The population
protected by vaccination was computed as all individuals arriving into the com-
partments SV and EV due to vaccination.
Vaccine efficacies. Vaccine efficacies in reducing susceptibility (VES), infectivity
(VEI) and hospitalization rate (VEH) were set using initial data from clinical trials
and real-word studies for the Pfizer-BioNTech vaccine16,19–23. Important to note,
that the efficacies reported in all these studies are not conditioned on infection
while they are in the models like ours. For a more complete discussion on this
topic, we refer the reader to the pedagogical work by Lipsitch and Kahn24 and the
report for England by the Scientific Advisory Group for Emergencies27.
The vaccine efficacy in reducing susceptibility (VES) was set based on vaccine
efficacies and effectiveness against infection (VEinfection) reported in clinical trials
and real-word studies, i.e.,
VEinfection  VES: ð13Þ
The vaccine efficacy in reducing infectivity (VEI) was assumed to be the same as
vaccine efficacy in reducing disease conditioned on infection (VEdisease∣infection), i.e.,
VEdisease∣infection≡VEI. VEdisease∣infection was calculated using the efficacy against
disease (VEdisease) reported in clinical trials as follows
VEdisease ¼ VEinfection þ ð1 VEinfectionÞVEdiseasejinfection: ð14Þ
The vaccine efficacy in reducing hospitalization rate (VEH) is equal to vaccine
efficacy against severe disease conditioned on disease (VEseverediseasejdisease), i.e.,
VEseverediseasejdisease  VEH . VEseverediseasejdisease was calculated using the vaccine
efficacy against severe disease (VEsevere disease) reported in trials as follows
VEseveredisease ¼ VEinfection þ ð1 VEinfectionÞVEdiseasejinfection
þ ð1 VEinfectionÞð1 VEdiseasejinfectionÞVEseverediseasejdisease:
ð15Þ
We used an optimistic and a pessimistic set of vaccine efficacies for VES, VEI
and VEH (Supplementary Table 1) based on the range of values for VEinfection,
VEdisease, and VEsevere disease reported in the literature16,19–23. For the optimistic set
explored in the main analyses (Figs. 6 and 7), we used VEinfection= 94%, VEdisease=
94%, and VEsevere disease= 98% (corresponding to VES= 94%, VEI= 0%, and VEH
= 67%)16,19,20,22,23,27. For the pessimistic set explored in sensitivity analyses
(Supplementary Fig. 7), we used VEinfection= 55%, VEdisease= 55%, and VEsevere
disease= 55% (corresponding to VES= 55%, VEI= 0%, and VEH= 0%)20,21,27.
Other efficacies reported in the literature for the Pfizer-BioNTech vaccine and
other existing vaccines fall in between the optimistic and pessimistic values we
used. This broad range of values is also relevant in case the market share of
different vaccine brands in Portugal gets changed throughout 2021.
Note that both the optimistic and pessimistic sets imply that the infectivity of
breakthrough cases in vaccinated persons is the same as infectivity of cases in
unvaccinated persons (VEI= 0%). Therefore, we included sensitivity analyses for
this parameter (Supplementary Fig. 11 and Supplementary Table 6) by taking two
additional values (Supplementary Table 1): VEI= 50% that corresponds to 50%
infectivity of vaccinated persons relative to infectivity of unvaccinated persons and
VEI= 100% that is a best-case scenario implying that breakthrough cases are not
infectious at all.
Summary of sensitivity analyses. The sensitivity analyses have been conducted
with respect to (i) timings of different relaxation steps where Step 3 occurs on 1
August instead of 1 October 2021 (Supplementary Fig. 6; Scenario 4); (ii) pessi-
mistic set of vaccine efficacies (Supplementary Figs. 7, 8 and Supplementary
Table 2; Scenario 4); (iii) sensitivity to infectivity of breakthrough cases in vacci-
nated persons (Supplementary Fig. 11 and Supplementary Table 6); (iv) behavior
compensation post-vaccination modeled as a return to pre-pandemic contact rates
among vaccinated persons as compared to unvaccinated persons who may con-
tinue to have reduced contact rates due to control measures (Supplementary
Figs. 7, 8 and Supplementary Table 2; Scenario 4); (v) the maximum vaccination
coverage in different age groups decreasing with age, i.e., the coverage for ages
[0,20), [20,50), [50,80), and 80+ was 0%, 75%, 85%, and 90%, respectively (Sup-
plementary Figs. 9 and 10; Scenarios 1, 2, 3 and 4). In all cases, the comparison was
done based on the cumulative median number of hospitalizations after the start of
the relaxation of measures until the end of the study period.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All datasets analyzed and generated in this study are publicly available at https://github.
com/lynxgav/COVID19-vaccination57.
Code availability
The codes reproducing the results of this study are publicly available at https://github.
com/lynxgav/COVID19-vaccination57.
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